Tacrolimus in hematopoietic stem cell transplantation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 7, 2009, Pages 835-841

  Fortune, Kara ^a   Couriel, Daniel ^b  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b Tennessee Oncology   (United States)

Author keywords

Calcineurin inhibitor; FK506; Graft versus host disease; Hematopoietic stem cell transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN A; INSULIN; METHOTREXATE; METHYLPREDNISOLONE; NUCLEAR FACTOR; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIVER VEIN OBSTRUCTION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; VEIN OCCLUSION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 67650729785     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903044959     Document Type: Review

References (45)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-674
2. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51:443-447
3. Davies JK, Lowdell MW. New advances in acute graft-versus-host disease prophylaxis. Tranfus Med 2003;13:387-397 (Pubitemid 37549036)
4. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-2068 (Pubitemid 30696232)
5. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92(7):2303-2314 (Pubitemid 28452971)
6. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004;33:613-622 (Pubitemid 38455923)
7. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004;10:246-258 (Pubitemid 38456203)
8. Ruutu T, Volin L, Parkkali T, et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000;96:2391-2398 (Pubitemid 30745260)
9. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995;85:3746-3753
10. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34:621-625 (Pubitemid 39341543)
11. Furlong T, Kiem HP, Appelbaum FR, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008;14:531-537
12. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplantation 2004;34:331-337 (Pubitemid 39172440)
13. Gorman K, Henslee-Downey PJ, Carey G, et al. Control of graft-versus-host disease (GVHD) reduces cost of bone marrow transplantation. Blood 1991;78:231a
14. Griffiths RI, Bass EB, Powe NR, et al. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993;12:43-48 (Pubitemid 23231034)
15. Tanaka H, Kuroda A, Marusawa H, et al. Structure of FK506: a novel immunosuppressant isolated from streptomyces. J Am Chem Soc 1987;109:5031-5033 (Pubitemid 17112542)
16. Kobayashi M, Tamura K, Katayama N, et al. FK506 assay past and present-characteristics of FK506 ELISA. Transplant Proc 1991;23:2725-2729
17. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from streptomyces: I. Fermentation, isolation, and physiochemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-1255
18. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from streptomyces: II. Immunosuppressive effect of FK-506 in-vitro. J Antibiot (Tokyo) 1987;40(9):1256-1265 (Pubitemid 17138110)
19. Sharkey J, Jones PA, McCarter JF, et al. Calcineurin inhibitors as neuroprotectants: focus of tacrolimus and cyclosporine. CNS Drugs 2000;13(1):1-13 (Pubitemid 30055663)
20. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46(4):746-794 (Pubitemid 23331067)
21. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54(6):925-975 (Pubitemid 27526900)
22. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59(2):323-389 (Pubitemid 30168519)
23. Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NAFT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995;92:11205-11209
24. Mouzaki A, Rungger D. Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated of drug-treated naïve and memory T-helper cells. Blood 1994;84:2612-2621 (Pubitemid 24317394)
25. Fay JW, Wingard JR, Antin JH, et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996;87:3514-3519 (Pubitemid 26115386)
26. Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of FK506: preclinical and clinical studies. Transplant Proc 1990;22:52-56 (Pubitemid 20112753)
27. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991;23:2736-2740
28. Boswell GW, Bekersky I, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998;21:23-28
29. Prograf Package Insert. Astellas Pharma US, Inc. Deerfield, IL, USA. 2006
30. Alak AM, Lizak PP. Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay. Ther Drug Monit 1996;18:267-272 (Pubitemid 26159578)
31. Perotti BY, Prueksaritanont T, Benet LZ. HPLC assay for FK506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. Pharm Res 1994;11:844-847 (Pubitemid 24210619)
32. Jusko WJ, D'Ambrosio R. Monitoring tacrolimus concentrations in plasma and whole blood. Trans Proc 1991;23:2732-2735
33. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001;40(4):293-295 (Pubitemid 32458154)
34. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-430
35. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22:57-59 (Pubitemid 20112754)
36. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-290
37. Bekersky I, Dressler D, Mekki Q. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001;41(2)176-182 (Pubitemid 32106056)
38. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001;41:289-297 (Pubitemid 32184981)
39. Przepiorka D, Ippoliti C, Khouri I, et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 1996;62:1806-1810 (Pubitemid 27014543)
40. Uberti JP, Silver SM, Adams PT, et al. Tacrolimus and methotrexate for the prophylaxis of acute graft versus host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1997;19:1233-1238 (Pubitemid 27302734)
41. Nash RA, Pineiro LA, Storb R, et al. KF506 in combination with methotrexate for the prevention of graft versus host disease after marrow transplantation from matched unrelated donors. Blood 1996;88:3634-3641 (Pubitemid 26365603)
42. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and mini-dose methotrexate for prevention of acute graft versus host disease after matched unrelated donor marrow transplantation. Blood 1996;88:4383-4389 (Pubitemid 26399187)
43. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft verus host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:181-185 (Pubitemid 32725719)
44. Couriel D, Thall P, Mickler K, et al. Phase I/II randomized study comparing two different tacrolimus blood levels for the prevention of graft-versus-host disease (GVHD) [abstract]. Blood 2005;106:142
45. Wong R, Shahjahan M, Xuemei W, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005;11(2):108-114 (Pubitemid 40186207)